Targeted Next-Generation Sequencing of 51 Genes Involved in Primary Electrical Disease
Dorien Proost1, Johan Saenen2, Geert Vandeweyer1
1Center of Medical Genetics, Faculty of Medicine and Health Sciences, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium.
Insights
A new genetic test accurately screens for primary electrical diseases (PED), a group of inherited heart rhythm disorders. This reliable assay identifies genetic variants, aiding in the diagnosis of cardiac arrhythmias and sudden cardiac death risk.
Area of Science:
- Cardiovascular Genetics
- Molecular Diagnostics
- Genomic Medicine
Background:
- Primary electrical disease (PED) comprises inherited cardiac arrhythmia syndromes.
- These conditions can cause sudden cardiac death without apparent structural heart issues.
- Diagnostic challenges arise from PED's clinical and genetic diversity.
Purpose of the Study:
- To develop and validate a targeted gene panel for next-generation sequencing of 51 PED-associated genes.
- To establish a reliable diagnostic tool for primary electrical diseases.
Main Methods:
- Developed a targeted gene panel assay (PED Multiplex Amplification of Specific Targets for Resequencing Plus).
- Utilized next-generation sequencing on MiSeq platform.
- Validated the panel using 39 control samples, achieving 100% analytical sensitivity and 99.9% specificity.
Main Results:
- Applied the validated assay to 114 PED patients.
- Identified 107 variants across 36 genes.
- Classified 18 variants as pathogenic/likely pathogenic, 54 as unknown significance, and 35 as likely benign.
Conclusions:
- The developed assay is a proficient and highly reliable tool for routine screening of primary arrhythmias.
- This genetic testing approach aids in diagnosing patients with primary electrical diseases.
- The panel facilitates the identification of disease-causing variants in inherited cardiac arrhythmia syndromes.
Abstract:
Primary electrical disease (PED) is characterized by cardiac arrhythmias, which can lead to sudden cardiac death in the absence of detectable structural heart disease. PED encompasses a diversity of inherited syndromes, predominantly Brugada syndrome, early repolarization syndrome, long QT syndrome, short QT syndrome, arrhythmogenic right ventricular cardiomyopathy, and catecholaminergic polymorphic ventricular tachycardia. To overcome the diagnostic challenges imposed by the clinical and genetic heterogeneity of PED, we developed a targeted gene panel for next-generation sequencing of 51 PED genes. The amplified samples were sequenced on MiSeq. To validate the panel, 20 Human Polymorphism Study Center samples and 19 positive control samples were used, with a total of 1479 variants. An analytical sensitivity and specificity of 100% and 99.9% were obtained. After validation, we applied the assay to 114 PED patients. We identified 107 variants in 36 different genes, 18 of which were classified as pathogenic or likely pathogenic, 54 variants were of unknown significance, and 35 were classified as likely benign. We can conclude that the PED Multiplex Amplification of Specific Targets for Resequencing Plus assay is a proficient and highly reliable test to routinely screen patients experiencing primary arrhythmias.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Acute Coronary Syndrome III: Diagnostic Studies
Electrocardiogram
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...


